Effects of Imipenem Cilastatin combined with Amikacin on Immune Function and Inflammatory Factors in Patients with Severe Pneumonia
Objective To explore the effects of imipenem cilastatin combined with amikacin on immune function and inflammatory factors in patients with severe pneumonia.Methods A total of 300 patients with severe pneumonia who received treatment in Panjin Central Hospital from January 2022 to August 2023 were selected as the study objects and divided into control group and observation group according to random number table method,with 150 cases in each group.The control group was treated with imipenem and cilastatin,and the observation group was treated with amikacin on the basis of control group.The immune function(CD4+,CD8+,CD3+,CD4+/CD8+),inflammatory factors[serum calcitonin(PCT),interleukin-8(IL-8),tumor necrosis factor-α(TNF-α)]and lung function[first second forced expiratory volume(FEV1),forced vital capacity(FVC),arterial blood oxygen Partial pressure(PaO2),partial pressure of Arterial Carbon dioxide(PaCO2)]were compared between the two groups.Results After treatment,the levels of CD4+,CD3+and CD4+/CD8+in the observation group were higher than those in the control group,and the levels of CD8+were lower than those in the control group,with statistical significance(P＜0.05).After treatment,the levels of PCT,IL-8 and TNF-α in observation group were lower than those in control group(P＜0.05).After treatment,FEV1,FVC and PaO2 in the observation group were higher than those in the control group,and PaCO2 was lower than those in the control group,with statistical significance(P＜0.05).Conclusion Imipenem and cilastatin combined with amikacin are effective in the treatment of severe pneumonia,which can improve the immune function,reduce inflammation and improve respiratory function.
Severe pneumoniaImipenem cilastatinAmikacinImmune functionInflammatory indicators
国家科技期刊平台
NSTL
万方数据
